Quote | Compass Therapeutics Inc. (OTCMKTS:CMPX)
Last: | $3.98 |
---|---|
Change Percent: | 9.04% |
Open: | $3.65 |
Close: | $3.98 |
High: | $3.995 |
Low: | $3.995 |
Volume: | 7,020 |
Last Trade Date Time: | 11/02/2021 04:54:36 pm |
News | Compass Therapeutics Inc. (OTCMKTS:CMPX)
2024-06-20 03:14:50 ET Summary Compass Therapeutics is an oncology-focused biotech developing novel immunotherapies for solid tumors, with a focus on gastrointestinal cancers. Their most advanced candidate, CTX-009, targets DLL4 and VEGF in biliary tract cancer, showing promising ...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside cha...
Message Board Posts | Compass Therapeutics Inc. (OTCMKTS:CMPX)
Subject | By | Source | When |
---|---|---|---|
Compass to review latest phase 2 progress with | marketmanallm | investorshub | 12/21/2022 6:51:49 PM |
Reminder $CMPX is Compass Therapeutics ,,,EF Hutton new | marketmanallm | investorshub | 12/16/2022 2:42:53 PM |
https://www.streetinsider.com/Corporate+News/Compass+Therapeutics%2C+Inc+%28CMPX | marketmanallm | investorshub | 12/01/2022 3:23:52 PM |
amazing no one posts on any $CMPX boards | marketmanallm | investorshub | 11/12/2022 4:23:59 PM |
The proper company name associated with $CMPX symbol | marketmanallm | investorshub | 10/21/2022 2:33:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Compass Therapeutics Inc. Company Name:
CMPX Stock Symbol:
OTCMKTS Market:
Compass Therapeutics Inc. Website:
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside cha...
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Sc...
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors....